TDACU - Translational Deve... Stock Analysis | Stock Taper
Logo
Translational Development Acquisition Corp.

TDACU

Translational Development Acquisition Corp. NASDAQ
$12.00 0.34% (+0.04)

Market Cap $263.57 M
52w High $17.29
52w Low $10.31
P/E -16.97
Volume 603
Outstanding Shares 24.63M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 $281.16K $1.33M 0% $0.06 $-281.16K
Q4-2025 $0 $162.34K $1.6M 0% $0.07 $-162.34K
Q3-2025 $0 $213.66K $1.66M 0% $0.08 $-213.66K
Q2-2025 $0 $221.13K $1.62M 0% $0.07 $-221.13K
Q1-2025 $0 $347.41K $1.48M 0% $0.37 $-347.41K

What's going well?

The company is still able to report a net profit, likely from investments or other non-operating sources. Share count is stable, so existing shareholders are not being diluted.

What's concerning?

There is no revenue and operating losses are getting worse. Profits come only from 'other' income, not from the actual business, making results unsustainable.

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $24.63K $183.35M $6.9M $176.45M
Q4-2025 $29.79K $181.7M $6.58M $175.12M
Q3-2025 $47.15K $179.98M $6.46M $173.52M
Q2-2025 $35.26K $178.18M $6.32M $171.86M
Q1-2025 $206.6K $176.6M $6.36M $170.24M

What's financially strong about this company?

The company has a very large equity cushion and almost no long-term debt. Most of its assets are in long-term investments, and there are no hidden risks or goodwill write-downs to worry about.

What are the financial risks or weaknesses?

Cash is extremely low, and current liabilities are much higher than current assets, so the company could face a cash crunch. Debt, while small overall, has increased sharply and is all due within a year, which could be risky if cash doesn't improve.

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $1.33M $-305.16K $0 $300K $-5.16K $-305.16K
Q4-2025 $1.6M $-117.36K $0 $100K $-17.36K $-117.36K
Q3-2025 $1.66M $-88.11K $0 $100K $11.89K $-88.11K
Q2-2025 $1.62M $-171.34K $0 $0 $-171.34K $-171.34K
Q1-2025 $1.48M $-231.57K $0 $0 $-231.57K $-231.57K

What's strong about this company's cash flow?

The company can still access debt markets and has not diluted shareholders with new stock. Capital spending is minimal, so cash burn isn't due to big investments.

What are the cash flow concerns?

Core operations are burning more cash each quarter, and the business is now highly dependent on borrowing just to keep going. Cash on hand is very low, and there's no sign of improvement.

5-Year Trend Analysis

A comprehensive look at Translational Development Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

TDACU benefits from a cash-backed structure with no traditional debt, relatively low ongoing operating costs, and positive reported net income driven by financial items. Its design gives it a pool of capital and a public listing that can be attractive to a private company seeking to go public quickly.

! Risks

Key risks center on the absence of any operating business, negative operating cash flow, negative equity, and complete reliance on finding and closing a suitable acquisition within a set deadline. The disconnect between accounting profits and cash burn, along with significant shareholder payouts, raises questions about sustainability if no transaction materializes.

Outlook

The company’s future is binary: either it successfully merges with a compelling target, at which point its financial profile will be completely transformed, or it fails to do so and is likely wound down with capital returned. Until a deal is announced and detailed, the current financials mainly describe a temporary financing vehicle rather than a going concern with predictable earnings or growth.